Fluticasone Furoate/Vilanterol Trifenatate

糠酸氟替卡松/三苯乙酸维兰特罗

Report date: 2026/05/13 20:02:10

Base Information

Drug NameFluticasone Furoate/Vilanterol Trifenatate
Drug Alias Nameビランテロールトリフェニル酢酸塩・フルチカゾンフランカルボン酸エステル糠酸氟替卡松维兰特罗吸入粉雾剂Fluticasone Furoate and Vilanterol TrifenatateVilanterol Trifenatate/Fluticasone FuroateFluticasone-furoate/vilanterol +[23] 
ClassificationSmall molecules > Steroids
Mechanisms of ActionGlucocorticoid receptor agonistsBeta-2 adrenergic receptor agonists
TargetsBeta-2 adrenergic receptorGlucocorticoid receptor
Therapy Area/IndicationsCardiovascular DiseasesPulmonary Disease, Chronic ObstructiveAsthma +[4] 
Global Approved IndicationsPulmonary Disease, Chronic ObstructiveAsthma
Approved Indications in ChinaPulmonary Disease, Chronic ObstructiveAsthma
Original Approved Country/TerritoryUnited States
Original Approved Date2013/05/10
Country/TerritoryCzechiaBelgiumBosnia and Herzegovina +[45] 
CombinationsYes Fluticasone FuroateVilanterol Trifenatate
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesGlaxosmithkline Biologicals SA
China Registration ClassN/A

Develop Information

Active CompaniesRoyal College Of Surgeons In Ireland - Medical University Of BahrainGlaxosmithkline PlcGlaxosmithkline (Ireland) Ltd +[6] 
Inactive CompaniesSandoz
Active IndicationsPulmonary Disease, Chronic ObstructiveAsthma
Inactive IndicationsCardiovascular DiseasesRespiratory Tract Diseases

Other Information

ATC CodeR03AK10
Related LinksWikipediaKEGG